News and Trends 25 Apr 2016
Scottish Biopharma begins Cell Therapy trials for Late-Stage Cancer
TC BioPharm has began recruitment to a phase II/III trial with its lead candidate (ImmuniCell), a T-cell therapy now targeting skin,…
Melanoma
- Latest Posts
News and Trends 31 Mar 2016
Money Magnet Immunocore kicks off Trial for Eye Melanoma
Immunocore (UK) has enrolled its first patient for a phase I trial that will test its ImmTAC as a standalone…
News and Trends 3 Feb 2016
When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease
ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is…
News and Trends 1 Feb 2016
New Discovery unites Australia, Germany and UK Against Blood Cancers
Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and…
ADVERTISEMENT
News and Trends 25 Jan 2016
This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery
Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye cancer drug by the FDA. Uveal…
News and Trends 26 Sep 2015
Replimune smashes Oncolytic viral €26.8M series A financing round
Replimune is an Oxford (UK) biotech baby, having only been founded in April this year a spin-off of former US…
News and Trends 17 Jul 2015
TC BioPharm raises €1.7M to commence treatment in UK cancer patients
TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the…
News and Trends 3 Jul 2015
Lilly Cooperates with Immunocore to Fight Skin Cancer
Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore's lead T cell receptor-based drug, IMCgp100 is tested in…
News and Trends 18 Apr 2015
Another Partnership between Immunocore and MedImmune against Skin Cancer
Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics…
